Co-construction of CALM-Pain, a mindfulness-based chronic pain management program for Veterans to improve quality of life

Co-construction of CALM-Pain, a trauma-informed mindfulness-based chronic pain management program for Veterans to improve quality of life: A pilot mixed methods study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10637979

Enrollment

Registered

2025-10-28

Start date

2025-12-01

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of quality of life among veterans living with chronic pain Signs and Symptoms

Interventions

Trauma-informed and trauma-sensitive mindfulness-based program for chronic pain in Veterans. This is a single-arm study in order to develop and refine the program so that it meets the needs of Veteran

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Living with pain for more than 3 months 2. Able to communicate in French or English 3. Residing in Canada (Quebec or Ontario for Phase 2) 4. Having access to the Internet

Exclusion criteria

Exclusion criteria: 1. Having prior experience with a structured mindfulness program for chronic pain (Phase 2 only) 2. Active suicidal ideations or severe psychiatric diagnosis that prevents participation

Design outcomes

Primary

Measure	Time frame
Health-related quality of life assessed using the Short-Form Health Survey V2 (SF-12v2) at baseline (within the 2 weeks prior to start of the intervention), T1 (session 6 of the intervention), T2 (within 2 weeks of intervention completion) T3 (6 months after intervention completion)	—

Secondary

Measure	Time frame
1. Pain self-efficacy measured using the Pain Self-Efficacy Questionnaire at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion) 2. Pain catastrophizing measured using the Pain Catastrophizing Scale at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion). 3. Pain intensity measured using an 11-point Numeric Rating Scale at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion) 4. Psychological distress assessed using the Patient Health Questionnaire-4 at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion). 5. Pain resilience measured using the Pain Resilience Scale at Baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion) 6. Pain interference measured using the Brief Pain Inventory at Baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion), and T3 (6 months after intervention completion). 7. Posttraumatic stress symptoms measured using the PTSD checklist for DSM-5 (PCL-5) at Baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion). 8. Recruitment rates: The number and proportion	—

Measure

Time frame

1. Pain self-efficacy measured using the Pain Self-Efficacy Questionnaire at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion) 2. Pain catastrophizing measured using the Pain Catastrophizing Scale at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion). 3. Pain intensity measured using an 11-point Numeric Rating Scale at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion) 4. Psychological distress assessed using the Patient Health Questionnaire-4 at baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion). 5. Pain resilience measured using the Pain Resilience Scale at Baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion) 6. Pain interference measured using the Brief Pain Inventory at Baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion), and T3 (6 months after intervention completion). 7. Posttraumatic stress symptoms measured using the PTSD checklist for DSM-5 (PCL-5) at Baseline (within the 2 weeks prior to start of the intervention), T1 (mid-way through intervention sessions), T2 (within 2 weeks of intervention completion) and T3 (6 months after intervention completion). 8. Recruitment rates: The number and proportion

—

Countries

Canada

Contacts

Public ContactGabrielle Pagé

gabrielle.page@umontreal.ca+1 (0)514 890 8000 x 31601

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026